JMY

Across TCGA pan-cancer cohorts, JMY mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated JMY data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher JMY mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated JMY expression acts as an unfavorable survival marker, although some lineages such as GBM and HNSC show a favorable association.

PDAC, GBM, and HNSC are the cancer types where JMY mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.297	0.545	.003	18	view →
GBM	DFS	Quartile	All	0.843	0.570	.001	15	view →
HNSC	DFS	Tertile	All	0.814	0.548	.005	14	view →
CCRCC	DFS	Median	IV	0.137	0.674	.047	6	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.826	.017	5	view →
UCEC	DFS	Median	II,III,IV	0.536	0.880	.044	4	view →
LUAD	DFS	Median	II,III,IV	0.399	0.736	.027	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

JMY–PDAC (DFS)

Open the PDAC breakdown →